The European Medicines Agency (EMA) has issued a list of five preferred therapeutics for COVID-19 patients, including four monoclonal antibodies and Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib).
This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab.
The four monoclonal antibodies selected for the EC’s COVID-19 Therapeutics Strategy are also currently being assessed under the EMA’s rolling review pathway.
The European Medicines Agency (EMA) is currently assessing an application for the extension of a marketing authorisation for Olumiant for COVID-19.
The EMA, which plans to expand its preferred list to include 10 treatments, released the list for use by regulatory authorities in EU member states. The only COVID-19 treatment currently approved in the EU is Gilead Sciences’ Veklury (remdesivir).
Now that it has identified the first five therapeutics as part of the strategy, the EC has committed to drawing up a portfolio of at least ten potential COVID-19 therapeutics by October 2021.
Comments